18F-FDHT与人性别激素结合球蛋白预结合促进其在前列腺癌异种移植小鼠模型中的特异性蓄积
研究比较游离18F-FDHT与SHBG结合型18F-FDHT在前列腺癌异种移植小鼠模型中的摄取,发现SHBG-18F-FDHT在4小时时肿瘤摄取显著高于游离型,且可被恩扎卢胺阻断,作者认为预结合SHBG可实现小鼠前列腺癌AR的定量PET显像。
要点
- AR水平与前列腺癌细胞系对18F-FDHT及SHBG-18F-FDHT的摄取相关。
- 22Rv1荷瘤小鼠4小时SHBG-18F-FDHT的TBR为1.62±0.62,高于游离型0.81±0.08。
- 恩扎卢胺阻断AR后SHBG-18F-FDHT的TBR降至1.07±0.13,提示摄取具有特异性。
核心结论
- 18F-FDHT与SHBG预结合可对小鼠前列腺癌模型的AR水平进行准确且定量的PET显像。
- 该程序可能使PET显像用于研究AR靶向治疗的纵向效应,从而加速新药研发。
研究设计与样本
- 使用三种人前列腺癌细胞系及异种移植(LNCaP、22Rv1和PC3)比较游离18F-FDHT与SHBG结合型18F-FDHT的摄取。
- 体外检测两种配体的稳定性及与AR的竞争结合,体内用PET/CT动态测量两种示踪剂4小时内的摄取,并以AR拮抗剂恩扎卢胺竞争结合确定特异性。
主要发现
- AR水平与前列腺癌细胞系对18F-FDHT及SHBG-18F-FDHT的摄取相关。
- 游离型与SHBG结合型18F-FDHT在1小时和2.5小时细胞蓄积相似,SHBG-18F-FDHT在4小时后蓄积显著更高,提示SHBG受体介导的摄取解释后期时间点差异。
- 22Rv1荷瘤小鼠4小时SHBG-18F-FDHT平均肿瘤/本底比值(TBR)为1.62±0.62,高于游离18F-FDHT的TBR 0.81±0.08。
- 恩扎卢胺阻断AR后肿瘤摄取降低,SHBG-18F-FDHT的TBR为1.07±0.13,证实4小时蓄积的特异性。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 原文指出人类与啮齿类的一个差异是后者缺乏性激素结合球蛋白(SHBG)。
- 原文指出迄今尚无啮齿类18F-FDHT显像模型的报道。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Tremendous efforts are currently dedicated to the development of novel therapies targeting the androgen receptor (AR), the major driver of prostate cancer disease and its progression to castration resistance. The ability to noninvasively interrogate AR expression over time in murine models of prostate cancer would permit longitudinal preclinical analysis of novel compounds that could not otherwise be accomplished ex vivo. Although PET imaging with 16β-18F-fluoro-5α-dihydrotestosterone (18F-FDHT) has successfully quantified AR levels clinically, no rodent model of 18F-FDHT imaging has been reported so far. One difference between humans and rodents is the absence in the latter of the sex hormone-binding globulin (SHBG), a glycoprotein that binds to testosterone in the bloodstream, Here, we explore the role of SHBG in developing a working model of rodent AR imaging. Methods: Three human prostate cancer cell lines and xenografts (LNCaP, 22Rv1, and PC3) were used to examine the uptake of free 18F-FDHT and SHBG-bound 18F-FDHT. Both ligands were examined for stability and competitive binding to AR over time in vitro before in vivo studies. PET/CT imaging was used to dynamically measure the uptake of both tracers over 4 h, whereas specificity was determined by competitive binding with the AR antagonist enzalutamide. Results: AR levels correlated with the uptake of both 18F-FDHT and SHBG-18F-FDHT in prostate cancer cell lines. Interestingly, whereas both free and SHBG-bound 18F-FDHT had a similar cellular accumulation at 1 and 2.5 h, SHBG-18F-FDHT accumulated at significantly higher levels after 4 h-evidence that receptor-mediated uptake of SHBG accounted for later time-point differences. This observation was also seen in 22Rv1 tumor-bearing mice, in which SHBG-18F-FDHT exhibited a significantly increased uptake (average tumor-to-background ratio [TBR], 1.62 ± 0.62) in comparison to unbound 18F-FDHT (TBR, 0.81 ± 0.08) at 4 h. Furthermore, the specificity of the SHBG-18F-FDHT accumulation at 4 h was demonstrated by a reduced tumor uptake after AR blockade with enzalutamide (TBR, 1.07 ± 0.13). Conclusion: Prebinding of 18F-FDHT to SHBG allows accurate and quantitative PET imaging of AR levels in murine models of prostate cancer. This procedure may permit the use of PET imaging to study the longitudinal effects of AR-targeting therapies, accelerating novel-drug development.
引用
- Larimer BM, Dubois F, Bloch E, et al. Specific 18F-FDHT Accumulation in Human Prostate Cancer Xenograft Murine Models Is Facilitated by Prebinding to Sex Hormone-Binding Globulin. J Nucl Med. 2018. PMID: 29853654. doi:10.2967/jnumed.118.208785
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。